IX Biopharma Ltd announced that on Jan, 19 2026 it allotted and issued 1,028,400 new ordinary shares following the exercise of warrants at 0.06 Singapore dollars per share.

As a result, the company’s total issued share capital rose to 959,130,205 shares from 958,101,805 shares. The new shares will rank pari passu with existing shares and are expected to begin trading on the Singapore Exchange on or around Jan, 21 2026.

The latest transaction brings the cumulative number of warrants exercised to 4,170,760, representing 7.25% of all warrants previously issued. After this exercise, 53,338,719 warrants remain outstanding, each with an exercise price of 0.06 Singapore dollars and an expiry date of Jul, 18 2026.